Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) closed Tuesday at $13.04 per share, down from $13.64 a day earlier. While Intercept Pharmaceuticals Inc. has underperformed by -4.40%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ICPT fell by -23.52%, with highs and lows ranging from $21.86 to $10.81, whereas the simple moving average fell by -16.90% in the last 200 days.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
On January 11, 2022, B. Riley Securities Upgraded Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) to Buy. A report published by Goldman on August 20, 2021, Downgraded its rating to ‘Sell’ for ICPT. B. Riley Securities also Downgraded ICPT shares as ‘Neutral’, setting a target price of $18 on the company’s shares in a report dated May 25, 2021. H.C. Wainwright February 23, 2021d its ‘Neutral’ rating to ‘Sell’ for ICPT, as published in its report on February 23, 2021. BofA Securities’s report from January 15, 2021 suggests a price prediction of $27 for ICPT shares, giving the stock a ‘Underperform’ rating. Jefferies also rated the stock as ‘Hold’.
Analysis of Intercept Pharmaceuticals Inc. (ICPT)
Further, the quarter-over-quarter increase in sales is 12.50%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Intercept Pharmaceuticals Inc.’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -164.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and ICPT is recording an average volume of 764.39K. On a monthly basis, the volatility of the stock is set at 5.68%, whereas on a weekly basis, it is put at 4.82%, with a loss of -4.47% over the past seven days. Furthermore, long-term investors anticipate a median target price of $23.79, showing growth from the present price of $13.04, which can serve as yet another indication of whether ICPT is worth investing in or should be passed over.
How Do You Analyze Intercept Pharmaceuticals Inc. Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.60% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ICPT shares?
The recent increase in stakes in ICPT appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in ICPT has increased by 34.65% in the first quarter. The company now owns 3,560,752 shares of the stock, with a value of $71.86 million, following the purchase of 916,236 additional shares during the last quarter. SSgA Funds Management, Inc. made another increased to its shares in ICPT during the first quarter, upping its stake by 4.07%. During the last quarter, the company picked up 124,341 additional shares for a total stake of worth $64.09 million, bringing number of shares owned by the company to 3,175,925.
During the first quarter, BlackRock Fund Advisors added a 315,913 position in ICPT. Millennium Management LLC sold an additional -0.2 million shares in the last quarter, decreasing its holdings by -17.07%, now holding 0.98 million shares worth $19.71 million. At the end of the first quarter, Jacobs Levy Equity Management, In increased its ICPT holdings by 18.20% and now holds 0.92 million ICPT shares valued at $18.63 million with the added 0.14 million shares during the period. ICPT shares are owned by institutional investors to the tune of 80.60% at present.
